Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Degenhardt

Rheumatology Savannah, GA Medical Doctor

NPI 1467651711 CMS profile 157499

5400 Waters Ave, Savannah, GA 31404

Open in the dashboard

General payments

$12,175

582 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Degenhardt of Savannah, GA is reported in the CMS Open Payments database as having received $12,175 across 582 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,787 117
2024 General $2,412 101
2023 General $1,657 80
2022 General $1,934 92
2021 General $852 45
2020 General $759 42
2019 General $1,775 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Degenhardt
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Charles Degenhardt were reported at $2,787. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Charles Degenhardt Rheumatology median Middle half National median
2019 $1,775 $744 $153–$2,687 $163
2020 $759 $462 $98–$2,027 $114
2021 $852 $531 $101–$2,153 $132
2022 $1,934 $627 $125–$2,303 $149
2023 $1,657 $741 $145–$2,524 $160
2024 $2,412 $830 $166–$2,660 $164
2025 $2,787 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $2,169 92 payments
  2. AbbVie, Inc. $2,145 94 payments
  3. E.R. Squibb & Sons, L.L.C. $1,229 71 payments
  4. Novartis Pharmaceuticals Corporation $1,032 54 payments
  5. GlaxoSmithKline, LLC. $723 36 payments
  6. UCB, Inc. $701 40 payments
  7. Janssen Biotech, Inc. $696 33 payments
  8. Genentech USA, Inc. $645 26 payments
  9. Horizon Therapeutics plc $636 38 payments
  10. Genzyme Corporation $397 10 payments
  11. Other $1,802 88 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,088 580 payments
  2. Education $86 2 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,762 78 payments
  2. ORENCIA $1,229 71 payments
  3. Otezla $737 30 payments
  4. BENLYSTA $723 36 payments
  5. KRYSTEXXA Inflammation/Rare Disease $684 26 payments
  6. SIMPONI ARIA $639 30 payments
  7. KRYSTEXXA Krystexxa $586 34 payments
  8. COSENTYX $544 30 payments
  9. Cimzia $534 33 payments
  10. Actemra $495 20 payments
  11. Other $6,421 293 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,579

Median for Rheumatology: 1,511

Drug cost

$1,416,260

Median for Rheumatology: $1,139,948

Branded share of claims

26.4%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 84 $689,380
Simponi Golimumab Brand 32 $259,327
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 12 $212,680
Humira(Cf) Pen Adalimumab Brand 21 $147,562
Xeljanz Xr Tofacitinib Citrate Brand 13 $71,250
Hydroxychloroquine Sulfate Generic 279 $11,036
Methotrexate Methotrexate Sodium Brand 236 $5,842
Mycophenolate Mofetil Generic 40 $5,494
Duloxetine Hcl Generic 99 $2,236
Prednisone Generic 243 $2,196

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$2,518,921

Of which drugs: $2,302,250

Medicare patients

793

Average age 73

Services billed

202,632

599 women, 194 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 26%
Diabetes 23%
Ischemic heart disease 23%
Chronic kidney disease 21%
Depression 18%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 95 25,727 $868,309
Injection, golimumab, 1 mg, for intravenous use J1602 Office 129 61,015 $546,450
Injection, rituximab, 10 mg J9312 Office 28 4,720 $283,661
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 58 66,400 $237,719
Injection, tocilizumab, 1 mg J3262 Office 19 28,043 $132,004
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 28 3,390 $84,198
Injection, denosumab, 1 mg J0897 Office 28 2,161 $44,442
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 27 812 $181
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 42 170 $124

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $471
$471 — —
KRYSTEXXA
  • Amgen Inc. $265
$265 — —
KEVZARA
  • GENZYME CORPORATION $264
$264 — —
SKYRIZI
  • AbbVie, Inc. $178
$178 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $116
$116 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

582 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record